ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in its Phase I-B clinical trial for systemic lupus erythematosus (SLE) was administered with the dose of treatment, according to a Thursday filing with the Hong Kong bourse.
IMM0306 attaches to two specific proteins, CD47 and CD20, found on cancerous B cells and sticks more to CD20 than to CD47, making the cancer treatment more effective, the filing said.
The pharma company's shares were up by over 16%.
Price (HKD): $7.25, Change: $+1.0, Percent Change: +16.19%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。